カテゴリー： Global Markets Direct, 世界, 医療/バイオ

自閉症(Autism)の治療薬パイプライン動向（2015年上半期版）

【英語タイトル】Autism - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料（GMDHC6033IDB）・商品コード：GMDHC6033IDB
・発行会社（調査会社）：Global Markets Direct
・発行日：2015年1月22日
・ページ数：154
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD2,000 ⇒換算￥216,000見積依頼/購入/質問フォーム
Site License（同一国内共有可）USD4,000 ⇒換算￥432,000見積依頼/購入/質問フォーム
Global Site License（複数国内共有可）USD6,000 ⇒換算￥648,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
当調査レポートでは、世界における自閉症(Autism)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。

・イントロダクション
・自閉症(Autism)の概要
・自閉症(Autism)治療薬の開発
　　- パイプライン製品の概要
　　- パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・自閉症(Autism)パイプライン製品の概略
　　- 後期段階の製品
　　- 治験段階の製品
　　- 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・自閉症(Autism)治療薬開発に取り組んでいる企業：企業別製品パイプライン
・自閉症(Autism)治療薬の評価
　　- 単剤治療薬
　　- 併用治療薬
　　- 標的別
　　- 作用機序（MoA）別
　　- 投与経路（RoA）別
　　- 分子の種類別
・各薬剤のプロファイル：説明、作用機序、研究開発（R&D）の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Autism – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Autism – Pipeline Review, H1 2015’, provides an overview of the Autism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Autism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Autism Overview 10
Therapeutics Development 11
Pipeline Products for Autism – Overview 11
Pipeline Products for Autism – Comparative Analysis 12
Autism – Therapeutics under Development by Companies 13
Autism – Therapeutics under Investigation by Universities/Institutes 16
Autism – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Autism – Products under Development by Companies 21
Autism – Products under Investigation by Universities/Institutes 23
Autism – Companies Involved in Therapeutics Development 24
Addex Therapeutics Ltd 24
Avanir Pharmaceuticals, Inc. 25
BioCrea GmbH 26
BrainStorm Cell Therapeutics Inc. 27
Cellceutix Corporation 28
Confluence Pharmaceuticals LLC 29
Curemark, LLC 30
Edison Pharmaceuticals, Inc. 31
Egenix, Inc. 32
F. Hoffmann-La Roche Ltd. 33
Heptares Therapeutics Ltd. 34
Intra-Cellular Therapies, Inc. 35
MedDay 36
Merz Pharma GmbH & Co. KgaA 37
Mitsubishi Tanabe Pharma Corporation 38
Mnemosyne Pharmaceuticals, Inc. 39
Novartis AG 40
Omeros Corporation 41
Otsuka Holdings Co., Ltd. 42
Reviva Pharmaceuticals Inc. 43
Saniona AB 44
Sumitomo Dainippon Pharma Co., Ltd. 45
Teva Pharmaceutical Industries Limited 46
Autism – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
(dextromethorphan hydrobromide + quinidine sulfate) – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
acamprosate calcium – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ADX-88178 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
aripiprazole – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
carbetocin – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CM-AT – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CN-2097 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CNDO-201 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drug for Autism – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drug for Autism Spectrum Disorders – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
fingolimod hydrochloride – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
fluoxetine – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
glatiramer acetate – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
HTL-14242 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ITI-007 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
KM-391 – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
lurasidone hydrochloride – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MD-1103 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
memantine hydrochloride – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
oxytocin – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
oxytocin – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
RG-7314 – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
RP-5063 – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule to Modulate GABRA5 Receptor for Alzheimer’s Disease, Schizophrenia and Autism – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule to Target GPR63 for Autism – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules to Target Oxytocin for Autism and Anxiety Disorders – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Stem Cell Therapy for Autism – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Stem Cell Therapy for Neurodegenerative Disorders – Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
suramin hexasodium – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
vatiquinone – Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Autism – Recent Pipeline Updates 108
Autism – Dormant Projects 144
Autism – Discontinued Products 146
Autism – Product Development Milestones 147
Featured News & Press Releases 147
Jun 26, 2014: Coronado Biosciences Reports Topline Results from Investigator Initiated Pilot Study of TSO in Adults with Autism Spectrum Disorder 147
May 14, 2014: Coronado Biosciences Initiates Phase 2a Clinical Study of TSO in Pediatric Patients With Autism Spectrum Disorder 147
Dec 12, 2013: Coronado Biosciences Announces Presentation of Interim Data From Autism Study at Neuropsychopharmacology Meeting 147
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 148
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 148
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 149
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 149
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 150
Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model 150
Nov 12, 2012: Coronado Biosciences Announces Initiation Of Investigator-initiated Study Evaluating TSO In Autism Spectrum Disorders 151
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 154
Disclaimer 154

[List of Tables]
Number of Products under Development for Autism, H1 2015 11
Number of Products under Development for Autism - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Comparative Analysis by Unknown Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2015 23
Autism - Pipeline by Addex Therapeutics Ltd, H1 2015 24
Autism - Pipeline by Avanir Pharmaceuticals, Inc., H1 2015 25
Autism - Pipeline by BioCrea GmbH, H1 2015 26
Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2015 27
Autism - Pipeline by Cellceutix Corporation, H1 2015 28
Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2015 29
Autism - Pipeline by Curemark, LLC, H1 2015 30
Autism - Pipeline by Edison Pharmaceuticals, Inc., H1 2015 31
Autism - Pipeline by Egenix, Inc., H1 2015 32
Autism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 33
Autism - Pipeline by Heptares Therapeutics Ltd., H1 2015 34
Autism - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 35
Autism - Pipeline by MedDay, H1 2015 36
Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 37
Autism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 38
Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 39
Autism - Pipeline by Novartis AG, H1 2015 40
Autism - Pipeline by Omeros Corporation, H1 2015 41
Autism - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 42
Autism - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 43
Autism - Pipeline by Saniona AB, H1 2015 44
Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 45
Autism - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 46
Assessment by Monotherapy Products, H1 2015 47
Assessment by Combination Products, H1 2015 48
Number of Products by Stage and Target, H1 2015 50
Number of Products by Stage and Mechanism of Action, H1 2015 52
Number of Products by Stage and Route of Administration, H1 2015 54
Number of Products by Stage and Molecule Type, H1 2015 56
Autism Therapeutics - Recent Pipeline Updates, H1 2015 108
Autism - Dormant Projects, H1 2015 144
Autism - Dormant Projects (Contd..1), H1 2015 145
Autism - Discontinued Products, H1 2015 146

[List of Figures]
Number of Products under Development for Autism, H1 2015 11
Number of Products under Development for Autism - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 47
Number of Products by Top 10 Targets, H1 2015 49
Number of Products by Stage and Top 10 Targets, H1 2015 49
Number of Products by Top 10 Mechanism of Actions, H1 2015 51
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 51
Number of Products by Top 10 Routes of Administration, H1 2015 53
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53
Number of Products by Top 10 Molecule Types, H1 2015 55
Number of Products by Stage and Top 10 Molecule Types, H1 2015 55

【掲載企業】

Addex Therapeutics Ltd
Avanir Pharmaceuticals, Inc.
BioCrea GmbH
BrainStorm Cell Therapeutics Inc.
Cellceutix Corporation
Confluence Pharmaceuticals LLC
Curemark, LLC
Edison Pharmaceuticals, Inc.
Egenix, Inc.
F. Hoffmann-La Roche Ltd.
Heptares Therapeutics Ltd.
Intra-Cellular Therapies, Inc.
MedDay
Merz Pharma GmbH & Co. KgaA
Mitsubishi Tanabe Pharma Corporation
Mnemosyne Pharmaceuticals, Inc.
Novartis AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
Reviva Pharmaceuticals Inc.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited

★調査レポート[自閉症(Autism)の治療薬パイプライン動向（2015年上半期版）] (コード：GMDHC6033IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[自閉症(Autism)の治療薬パイプライン動向（2015年上半期版）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 自閉症(Autism)：治療薬パイプラインレビュー
    GMDHC10594IDB / Global Markets Direct / 2018年7月10日 / ...Autism - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H2 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape. Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H2 2018, provides comprehensive...
  • 神経線維腫症(Neurofibromatoses)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209278 / Global Markets Direct / 2016年12月21日 / 当調査レポートでは、世界における神経線維腫症(Neurofibromatoses)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・神経線維腫症(Neurofibromatoses)の概要 ・神経線維腫症(Neurofibromatoses)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Neurofibromatoses - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses – Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses (Genetic Disorders) pipeline landscape. Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors;...
  • 神経膠肉腫(Gliosarcoma)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209281 / Global Markets Direct / 2016年11月9日 / 当調査レポートでは、世界における神経膠肉腫(Gliosarcoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・神経膠肉腫(Gliosarcoma)の概要 ・神経膠肉腫(Gliosarcoma)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Gliosarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma – Pipeline Review, H2 2016, provides an overview of the Gliosarcoma (Oncology) pipeline landscape. Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other...
  • トキソプラズマ症(Toxoplasmosis)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209194 / Global Markets Direct / 2016年12月14日 / 当調査レポートでは、世界におけるトキソプラズマ症(Toxoplasmosis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・トキソプラズマ症(Toxoplasmosis)の概要 ・トキソプラズマ症(Toxoplasmosis)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Toxoplasmosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis – Pipeline Review, H2 2016, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape. Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious...
  • ケロイド(Keloids)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209191 / Global Markets Direct / 2016年12月30日 / 当調査レポートでは、世界におけるケロイド(Keloids)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・ケロイド(Keloids)の概要 ・ケロイド(Keloids)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Keloids - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids – Pipeline Review, H2 2016, provides an overview of the Keloids (Keloids) pipeline landscape. Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids...
  • 老眼：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209362 / Global Markets Direct / 2016年12月30日 / 当調査レポートでは、世界における老眼の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・老眼の概要 ・老眼治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Presbyopia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia – Pipeline Review, H2 2016, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia – Pipeline Review,...
  • バーキットリンパ腫(Burkitt Lymphoma)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209197 / Global Markets Direct / 2016年11月9日 / 当調査レポートでは、世界におけるバーキットリンパ腫(Burkitt Lymphoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・バーキットリンパ腫(Burkitt Lymphoma)の概要 ・バーキットリンパ腫(Burkitt Lymphoma)治療薬の開発 　　- パイプライン製品の概要 　　-...Burkitt Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkitt Lymphoma – Pipeline Review, H2 2016, provides an overview of the Burkitt Lymphoma (Oncology) pipeline landscape. Burkitt lymphoma is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. Symptoms include fever, night sweats, swollen lymph nodes and weight loss. The disease is more common in males and people with compromised immune systems, such as those with HIV/AIDS. Treatment includes chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkitt Lymphoma...
  • 野兎病(Tularaemia)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209350 / Global Markets Direct / 2016年11月30日 / 当調査レポートでは、世界における野兎病(Tularaemia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・野兎病(Tularaemia)の概要 ・野兎病(Tularaemia)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Tularaemia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2016, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape. Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands,...
  • 脂肪肉腫(Liposarcoma)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209263 / Global Markets Direct / 2016年12月14日 / 当調査レポートでは、世界における脂肪肉腫(Liposarcoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・脂肪肉腫(Liposarcoma)の概要 ・脂肪肉腫(Liposarcoma)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Liposarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma – Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape. Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liposarcoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by...
  • 退形成性星細胞腫(Anaplastic Astrocytoma)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209303 / Global Markets Direct / 2016年11月9日 / 当調査レポートでは、世界における退形成性星細胞腫(Anaplastic Astrocytoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・退形成性星細胞腫(Anaplastic Astrocytoma)の概要 ・退形成性星細胞腫(Anaplastic Astrocytoma)治療薬の開発 　　- パイプライン製品の概要 　　-...Anaplastic Astrocytoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma – Pipeline Review, H2 2016, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape. Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures....

    • ◆H&Iグローバルリサーチのお客様（例）◆